Tue, July 12, 2022

Andrew Fein Maintained (SYRS) at Strong Buy with Decreased Target to $60 on, Jul 12th, 2022

Andrew Fein of HC Wainwright & Co., Maintained "Syros Pharmaceuticals, Inc." (SYRS) at Strong Buy with Decreased Target from $100 to $60 on, Jul 12th, 2022.

Andrew has made no other calls on SYRS in the last 4 months.



There is 1 other peer that has a rating on SYRS. Out of the 1 peers that are also analyzing SYRS, 0 agree with Andrew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Andrew


  • Matt Cross of "Alliance Global Partners" Maintained at Strong Buy with Decreased Target to $100 on, Tuesday, May 17th, 2022